Oppenheimer & Co. Inc. Makes New Investment in Guardant Health, Inc. $GH

Oppenheimer & Co. Inc. bought a new stake in Guardant Health, Inc. (NASDAQ:GH) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 5,362 shares of the company’s stock, valued at approximately $548,000.

Several other hedge funds have also added to or reduced their stakes in GH. V Square Quantitative Management LLC purchased a new stake in shares of Guardant Health during the fourth quarter valued at approximately $27,000. Chesapeake Asset Management LLC bought a new stake in Guardant Health during the fourth quarter valued at approximately $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Guardant Health during the 4th quarter worth $31,000. First Pacific Financial purchased a new position in Guardant Health during the fourth quarter valued at $43,000. Finally, Optiver Holding B.V. raised its stake in shares of Guardant Health by 153.5% in the third quarter. Optiver Holding B.V. now owns 768 shares of the company’s stock worth $48,000 after buying an additional 465 shares during the period. 92.60% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have weighed in on GH shares. Mizuho set a $135.00 price target on shares of Guardant Health in a report on Friday, January 9th. Raymond James Financial reiterated an “outperform” rating and set a $129.00 price objective on shares of Guardant Health in a research report on Monday, February 23rd. JPMorgan Chase & Co. upped their price target on shares of Guardant Health from $130.00 to $135.00 and gave the company an “overweight” rating in a research note on Friday. Robert W. Baird started coverage on shares of Guardant Health in a report on Tuesday, February 17th. They issued an “outperform” rating and a $120.00 price target for the company. Finally, TD Cowen upped their price objective on Guardant Health from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Friday, February 20th. Nineteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $129.16.

Guardant Health News Roundup

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Guardant Health reported Q1 2026 revenue of $301.7 million, well above Wall Street expectations, with revenue up 48% year over year and oncology test volume rising sharply. Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
• Positive Sentiment: The company beat earnings estimates with a smaller-than-expected quarterly loss of $0.45 per share, signaling improving operating performance. Guardant Health (GH) Reports Q1 Loss, Beats Revenue Estimates
• Positive Sentiment: Guardant Health raised its 2026 revenue guidance, reinforcing confidence in continued demand and execution. Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
• Positive Sentiment: JPMorgan Chase & Co. raised its price target on GH to $135 from $130 and reiterated an overweight rating, implying further upside from current levels. Benzinga report on JPMorgan price target increase
• Neutral Sentiment: Investors are also digesting the company’s earnings call transcript and presentation for more detail on management’s outlook and product momentum. Guardant Health, Inc. (GH) Q1 2026 Earnings Call Transcript

Guardant Health Stock Up 3.7%

Guardant Health stock opened at $95.70 on Friday. The firm has a market cap of $12.69 billion, a P/E ratio of -28.23 and a beta of 1.48. The business has a fifty day moving average of $88.93 and a two-hundred day moving average of $96.92. Guardant Health, Inc. has a twelve month low of $36.36 and a twelve month high of $120.74.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The firm had revenue of $281.27 million during the quarter, compared to analysts’ expectations of $269.74 million. The company’s revenue was up 39.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.62) EPS. Equities analysts expect that Guardant Health, Inc. will post -2.87 earnings per share for the current year.

Insider Transactions at Guardant Health

In related news, CFO Michael Brian Bell sold 3,000 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $87.04, for a total value of $261,120.00. Following the transaction, the chief financial officer owned 43,601 shares in the company, valued at approximately $3,795,031.04. This represents a 6.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Medina Manuel Hidalgo sold 1,300 shares of Guardant Health stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $91.54, for a total transaction of $119,002.00. Following the sale, the director owned 1,193 shares of the company’s stock, valued at approximately $109,207.22. The trade was a 52.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 8,596 shares of company stock worth $775,767 in the last ninety days. Corporate insiders own 6.10% of the company’s stock.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.